目的 回顧性分析利巴韋林注射液在武漢市第三醫(yī)院新型冠狀病毒肺炎（COVID-19）患者中的使用情況、不良反應(yīng)及藥學(xué)監(jiān)護(hù)，以期為抗病毒合理用藥提供理論依據(jù)。方法 借助醫(yī)院信息系統(tǒng)提取2020年1月1日-2020年3月17日于武漢市第三醫(yī)院治療時(shí)使用過利巴韋林注射液的32例COVID-19患者的臨床資料。對(duì)利巴韋林的用藥情況、藥物不良反應(yīng)進(jìn)行分析，并提出藥學(xué)監(jiān)護(hù)計(jì)劃。結(jié)果 利巴韋林的使用存在劑量不足、配制濃度過高、療程較長(zhǎng)、聯(lián)合用藥品種過多及特殊人群用藥不適宜的問題，其不良反應(yīng)發(fā)生率較高。結(jié)論 利巴韋林在治療COVID-19的使用還有待進(jìn)一步的規(guī)范，臨床用藥過程中應(yīng)密切關(guān)注不良反應(yīng)的發(fā)生，進(jìn)一步加強(qiáng)藥學(xué)監(jiān)護(hù)。

Objective The use, adverse reactions, and pharmaceutical care of Ribavirin Injection in patients with corona virus disease 2019 (COVID-19) in The Third Hospital of Wuhan were analyzed retrospectively, so as to provide theoretical basis for the rational use of antiviral drugs.Methods The hospital information system was used to extract the clinical data of 32 cases COVID-19 patients who had used Ribavirin Injection in The Third Hospital of Wuhan from January 1 to March 17, 2020. The situation of ribavirin use and adverse drug reactions were analyzed, and the pharmaceutical care plan was put forward. Results The use of ribavirin has some problems, such as insufficient dose, high concentration of ribavirin, long course of treatment, too many varieties of combined drugs and inappropriate use of drugs in special population, with a high incidence of adverse reactions. Conclusion The use of ribavirin in treatment of COVID-19 remains to be further standardized, and the occurrence of adverse reactions should be closely watched during the clinical medication process to further strengthen pharmaceutical care.

R974